Journal of Medical Economics

Papers
(The H4-Index of Journal of Medical Economics is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
Health outcomes and economic burden of hospitalized COVID-19 patients in the United States137
The Global South political economy of health financing and spending landscape – history and presence80
Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis46
Asian innovation in pharmaceutical and medical device industry – beyond tomorrow40
Iran, sanctions, and the COVID-19 crisis40
Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b239
How China controls the Covid-19 epidemic through public health expenditure and policy?38
Chronic wound prevalence and the associated cost of treatment in Medicare beneficiaries: changes between 2014 and 201930
Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer28
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison27
Setting and maintaining standards for patient-reported outcome measures: can we rely on the COSMIN checklists?26
Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United Sta25
Economic implications of the modern treatment paradigm of glioblastoma: an analysis of global cost estimates and their utility for cost assessment23
The societal economic value of COVID-19 vaccines in the United States23
Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China22
Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endom21
Mean lifetime survival estimates following solid organ transplantation in the US and UK21
A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome19
Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder18
0.088131189346313